Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well said ,
No deal , no milestone payment,
Crash n burn
AIM
Gravy train keeps going till then.....
Utah, I'm not pumping it- I am stating facts in regards to where we are with what we have- I'm realistic as I said last night without a deal or milestone this year we could be finished it is AIM after all so we could crash and burn. But the Tyk2 market is saying something else (the BMS/Celgene deal could not have happened otherwise and BMS would have been seen as crazy or suicidal to be dumping Otezla which is reaching sales of $1.2bn per year- they obviously believe in the Tyk2/Jak market) and Sierra are going full throttle we have heard the webcasts and seen their posters.
Nothing is guaranteed of course so it could all go bellys up.
(Can we stop calling them "Trails" please)
Ahfam3.
I (and others I guess) wish I shared your optimism, albeit based upon some interesting looking evidence.
It's not the news on the products' progress which is bugging folk it is the continuing silence from Pampisford on what the BOD are doing to get this company's name up in lights as a potential leader in its field. If they are expecting someone to blow the trumpet for them then they are living in a dream world. As is stands at present we know absolutely nothing about their activities ( if there are any!) which is appalling. They are, no doubt being paid handsomely (by Us!) and we have a right to know how they are going about getting Sareum in the headlines.
I realise that some information is price sensitive but that is what the RNS system is there to cope with but day to day activities to improve the Company's image etc is a different matter.
C'mon Pampisford-let us know what you are up to and give us some indication that you ARE doing what is says on the tin
Stop pumping it ahfam this is not good news. I’m buying in when it goes to 3’s which will be mid July I reckon
We'll be okay- they have the money now to go for 1st in human on Tyk2 and with the BMS/Celgene thing happening- I'd be damned if no one was interested in us. It's a multi-billion dollar market and we are the only Tyk2 available for licence and have indications in Lupus (US Army verified report), Cancer (a new indication) and auto-immune (we smashed Pfizer's marketed Tofa which reached $1.8bn in sales in 2018- Pfizer funded the trials, they know how good it is- Pfizer are big enough to have used anyone else so it is testament to Dr's Tim and John work).
I think we just need to ahfam we currently have nothing in game commercially just like Val
Sure Utah I get what your saying- but then Val don't have a compound licenced in the US looking at a potential fast-track in ovarian cancer, PARP combo with Janssen and multi-applicable in other cancer types like Chk1.
The issue with Sar for years is they have always been close to a deal while the shares get continually diluted with placings to continue paying themselves nice wages.
The usual Aim carry on.
It’s hard to have any faith in a ‘management’ that continually promises, continually dilutes, continually look after themselves with big wages and delivers....nothing.
Ahfam ... Nicely worded ... and I agree with what you are saying
Last night when I first saw the RNS's I could only picture anger and frustration and blurted out that frustration on this BB. However, having considered this overnight, I tend to agree with what Potnak was saying in that this may actually be a catalyst/trigger/action required to progress to the elusive TYK2 (or parker would tweet TKP3) deal.
So even though the SP may get hammered over the next few weeks I will now continue to hold for either the milestone or deal(s) .... Just going to be longer than i was hoping for
Just hope they can get the allotted 500K as if this sinks below 0.4 then it will be the MM's making the money and preventing this 500K being accumulated
GLALTHERS ... disappointing news but hopefully we may get good news later this year
Here is a question though ... if the deal is likely to significantly jump the SP then why would TM, JT, Parker + Wife and the other NED not have grabbed £10K's worth if it was likely to double/treble/10-fold ??? In their positions I would have ... thats the only thing worries me regarding the expected timeline
Doesn’t answer the non information and dilution sorry you are being blind just like Val which has lost 90% of value over years even though they an amazing compound
Utah, don't get me wrong. I am well aware of the situation, of course if no money comes in this year through a milestone or licencing deal it will probably be curtains. But with Tyk2 getting so much press and the BMS/Celegene deal indicating towards Tyk2 being a major driving force for it, it just seems unlikely that no one would be interested in Sar's compounds. The Pfizer Tofa trials are there to be seen and we now have a cancer indication as well Sri and the US Army liked what they saw in Lupus trials and we know that SKIL can create potentially blockbuster compounds from the Chk1 progression via Sierra which looking increasingly likely to go for an orphan fast-track in ovarian cancer. So I'm not deluded, it's just a waiting game in and general pharma behaviour in AIM.
I think you are deluded ahfam sorry. It means no commercial deal in negotiation, no milestone payment imminent and it means a year of stagnation. Don’t kid your self. Refer to Valirx
No real bad news here chaps. We still have potentially two Tyk2 as Tim and John put it 'Best in Class' compounds available for licence. You saw some of the $bn deals in the finals RNS some pre-clinical. This raise will be used to hasten them to trials and if we go to phase 1 then the price goes up. As Fadec puts it BMS are ditching a $1.2bn per year treatment for the bigger picture- Tyk2 is hot everyone is taking about it and Sar are primed for a takeover or licence. You only have to look at the Sar Tyk2 auto-immune against Pfizer's $1.8bn Tofa to see how selective it was a with a higher dose which Tofa could not achieve Sar's showed trace after 30 days I believe- that's cured no Arthritis. This is massive chaps, the science is still good.
Mixed thoughts as the price isn’t good, only just purchased some recently but I did keep a chuck for this type of eventuality, I think that the merger of BMS and Celgene with the divestment of Otezla a $2B a year drug has moved things and their progress, Sareum on the other hand being the only one left to license, I personally would rather not wait for a milestone payment to progress TYk2 let’s get it into registration and then let’s see if one of the big boys get their paychecks out, I bit flabbergasted but positive step to deal and progressing into clinic!
Hi Potnak - I agree......something is happening in the background.
Back in Feb 2016, SAR announced that our CHK1 was going into trials under a collaboration deal with CRT/CPF. As part of the deal SAR had to make a financial commitment of almost 800k. Within a few months (May 2016) the trials had been submitted and approved.
So IMHO, SAR having to make another financial commitment to *progress* our TYK2 compounds sounds like history repeating itself. I believe SAR have been working hard in the background and we will now begin to see their plans fall into place. They will have the clinical plans designed and applications ready to go.
Also of note - Sierra (back then Pro-nai) would have been under negotiations with the CPF for months and months prior to the licence deal which was announced in Sept 2016. I still also believe that a company is doing due diligence on our TYK2's and maybe SAR are using this as a signal to them to either p*ss or get off the pot.......has to be similar to the Sierra licence, they don't happen overnight but are certainly announced that way.
Let's not forget, we are the 100% owners (well for now - I sense that maybe ICR/CRT will be announced as a partner) of the only other TYK2 *compounds* available for licence in a very hot biotech market.
I sense the frustration with everyone here and also share the frustration, but we must continue to look at the bigger picture.
I will be having a small top up for sure on the inevitable drop tomorrow.
GLA
Aber - this is just progress TYK2, no operating costs. The placing will just be enough to satisfy the trial application which they are obligatted to do. As JT says, it looks like the board still believe something else is pending. This will hopefully cover operating costs. Once these shares are admitted, we'll get news on what the funds were for. IMO, it will be trial application. My average is 0.74 and its shit looking at the loss but I see this as progress. The SP has nothing to do with Parker, the sp will rise with progress. I'm feeling excited about this.
£500k minus costs... as you say, it means the company is sailing close to the wind again... no idea how much is left in the kitty but if you have to drop the price by nearly a 1/3 to get the cash you might as well have gone for £750k-million and have done with it...
skimping on money raising is pointless... the pain is the same and so ae the repercussions... would have meant the co was secure for the rest of the year... if the company can't get good news by end of the year then i've no idea what anyone is doing here...
the only good thing is, what with it being pb, there's a strong likelihood that, if the demand is there, they'll just chuck in an extra £100-200k to the pot and tell you about it afterwards.
if they don't then that'll tell you demans dried up (unless the underwriter takes ona wedge of 'em).
gla..
Potnak - only 500k to progress TYK2 and for working capital .... to me that’s just too little to apply for given that working capital now means 5 * salaries ( rather than 3)
I would have been happier that they just went for the million+ so that they don’t run out and have to go to market again
The CHK1 trail was granted 4 months after the application. We'll get the application RNS in the next month IMO. Part of that application is securing the funds which we now have done.